person · Reporting owner
Borgman Anne Elizabeth
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Director | July 07, 2026 | July 09, 2026 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2036-07-06 | Direct | 6,800 |
Reported balance
After 2026-07-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-07 · Grant · Acquired 6,800 · Balance 6,800 F1: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027.
NextCure, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2036-06-17 | Direct | 2,340 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 2,340 · Balance 2,340 F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SUTRO BIOPHARMA, INC.
Report date May 01, 2025 · Filed May 05, 2025
Section 16 reporting ended · disclosed 2025-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,452 |
Ending reported balance
After 2025-05-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-05-01 · Exercise / conversion · Acquired 53,125 · Balance 106,223 Row 2 · 2025-05-01 · Exercise / conversion · Acquired 15,938 · Balance 122,161 Row 3 · 2025-05-01 · Tax withholding · Disposed 24,709 · Balance 97,452 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2027-02-28 | Direct | 21,875 |
Reported balance
After 2025-05-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-01 · Exercise / conversion · Disposed 53,125 · Balance 21,875 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 17,812 |
Reported balance
After 2025-05-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-01 · Exercise / conversion · Disposed 15,938 · Balance 17,812 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F5: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date.
F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025.
F5: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 20:11 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 6,800 | $5.29 Strike: $5.29 | $35,972.00 |
DisclosureSEC source: 0001108205-26-000092 · wk-form4_1783627883.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2036-07-06 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on July 7, 2027. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:14 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0000905148-26-003048 · form4.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,340 Underlying: Common Stock · 2,340 shares Expires 2036-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:30 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000905148-25-002243 · form4.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2035-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2026 and the date of the 2026 Annual Meeting of Stockholders. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:12 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 14,400 | $3.13 Strike: $3.13 | $45,072.00 |
DisclosureSEC source: 0001108205-25-000064 · wk-form4_1747944760.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,400 Underlying: Common Stock · 14,400 shares Expires 2035-01-27 F1 · date: This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan. F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 28, 2026. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 15,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011996 · form4-05052025_090507.xml · derivative · entry 5 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,812 Underlying: Common Stock · 15,938 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 53,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011996 · form4-05052025_090507.xml · derivative · entry 4 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 53,125 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date. F4 · derivative.exercise_date: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan and 2021 Equity Inducement Plan, in connection with her separation and transition from her position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 24,709 | $1.07 | $26,438.63 |
DisclosureSEC source: 0001415889-25-011996 · form4-05052025_090507.xml · nonDerivative · entry 3 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,452 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 15,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011996 · form4-05052025_090507.xml · nonDerivative · entry 2 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:45 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 53,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011996 · form4-05052025_090507.xml · nonDerivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006655 · form4-03042025_100306.xml · derivative · entry 6 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 11,250 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 4,621 | $1.59 | $7,347.39 |
DisclosureSEC source: 0001415889-25-006655 · form4-03042025_100306.xml · nonDerivative · entry 4 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,098 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006655 · form4-03042025_100306.xml · nonDerivative · entry 3 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006655 · form4-03042025_100306.xml · derivative · entry 5 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 37,500 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 15,405 | $1.59 | $24,493.95 |
DisclosureSEC source: 0001415889-25-006655 · form4-03042025_100306.xml · nonDerivative · entry 2 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,469 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:57 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006655 · form4-03042025_100306.xml · nonDerivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:05 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 1,600 | $3.13 Strike: $3.13 | $5,008.00 |
DisclosureSEC source: 0001108205-25-000008 · wk-form4_1738271120.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 1,600 shares Expires 2035-01-27 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 28, 2026. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 21:03 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000905148-24-001764 · form4.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2034-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2025 and the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:08 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 4,250 | $11.62 Strike: $11.62 | $49,385.00 |
DisclosureSEC source: 0001108205-24-000050 · wk-form4_1716494923.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2034-01-19 F1 · date: This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 20, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan. F2 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 20, 2025. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007182 · form4-03072024_090326.xml · derivative · entry 2 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-03-01 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:24 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 60,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007182 · form4-03072024_090326.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006267 · form4-03042024_090339.xml · derivative · entry 3 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually on the last calendar day of February, beginning on February 29, 2024, subject to continued service through each vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,126 | $4.91 | $64,448.66 |
DisclosureSEC source: 0001415889-24-006267 · form4-03042024_090339.xml · nonDerivative · entry 2 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,374 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:15 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006267 · form4-03042024_090339.xml · nonDerivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:30 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001140361-23-031187 · form4.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:05 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019599 · doc4.xml · derivative · entry 2 Borgman Anne Elizabeth · CIK 0001886388 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-28 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on February 28, 2024, subject to continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:05 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 175,000 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001209191-23-019599 · doc4.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: The option vests as to 1/4th of the total shares on February 28, 2024 and then 1/48th of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on February 28, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 21:12 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 85,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001108205-23-000012 · wf-form4_167459471417943.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-01-22 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 23, 2024), subject to the director's continued service with the Company. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 20:06 UTC | CURIS INC CRIS · Entity 8401 | GrantNon Qualified Stock Option · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-053658 · doc4.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2032-10-11 F1 · derivative.exercise_price: Options granted under the Fourth Amended and Restated 2010 Stock Incentive Plan and will vest over a period of four years with 25% of the shares underlying the stock option vesting on October 12, 2023, and an additional 6.25% of the shares vesting at the end of each successive three-month period thereafter until the options are fully vested on October 12, 2026, subject to Dr. Borgman's continued service on the Company's Board. F1 · derivative.exercise_date: Options granted under the Fourth Amended and Restated 2010 Stock Incentive Plan and will vest over a period of four years with 25% of the shares underlying the stock option vesting on October 12, 2023, and an additional 6.25% of the shares vesting at the end of each successive three-month period thereafter until the options are fully vested on October 12, 2026, subject to Dr. Borgman's continued service on the Company's Board. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 21:32 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0001567619-22-013372 · doc1.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2032-06-22 F1 · derivative.exercise_date: The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:05 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 10,384 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001567619-21-017920 · doc1.xml · derivative · entry 2 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2031-09-30 F2 · derivative.exercise_date: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:05 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001567619-21-017920 · doc1.xml · derivative · entry 1 Borgman Anne Elizabeth · CIK 0001886388 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2031-09-30 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on October 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.